Jenburkt Pharma

Which are the latest news on Jenburkt Pharma?

Why is Jenburkt Pharmaceuticals Ltd. falling/rising?

As of 03-Aug, Jenburkt Pharmaceuticals Ltd. is seeing a stock price increase to 1,090.75, driven by positive market sentiment, strong financial metrics, and heightened investor interest. The stock has gained 2.65% over the last three days and outperformed its sector today, indicating a favorable outlook.

As of 03-Aug, Jenburkt Pharmaceuticals Ltd. is experiencing a rise in its stock price, currently at 1,090.75, which reflects an increase of 13.85 (1.29%). This upward movement can be attributed to several factors. Firstly, the stock has been gaining for the last three days, with a total return of 2.65% during this period. Additionally, the stock outperformed its sector by 0.61% today, indicating positive market sentiment.<BR><BR>The stock reached an intraday high of Rs 1110, marking a 3.07% increase, which suggests strong buying interest. Furthermore, there has been a significant increase in investor participation, with delivery volume rising by 223.55% compared to the 5-day average, indicating heightened interest from investors.<BR><BR>From a financial perspective, the company is net-debt free and has demonstrated high management efficiency with a return on equity (ROE) of 18.99%. The recent quarterly profit after tax (PAT) has grown by 72.4% compared to the previous four-quarter average, and the operating profit to net sales ratio is at its highest level of 31.93%. These strong financial metrics contribute to a favorable outlook for the stock, despite its year-to-date performance being relatively flat at +0.09%.<BR><BR>Overall, the combination of recent positive price movements, increased investor participation, and strong financial performance are key reasons for the rising stock price of Jenburkt Pharmaceuticals Ltd.

When is the next results date for Jenburkt Pharmaceuticals Ltd.?

The next results date for Jenburkt Pharmaceuticals Ltd. is August 6, 2026.

The next results date for Jenburkt Pharmaceuticals Ltd. is scheduled for August 6, 2026.

Should I buy, sell or hold Jenburkt Pharmaceuticals Ltd.?

How big is Jenburkt Pharma?

As of 10th June, Jenburkt Pharmaceuticals Ltd. has a market capitalization of 519.00 Cr, with recent net sales of 168.74 Cr and a net profit of 34.73 Cr. Shareholder's funds are 171.78 Cr, and total assets amount to 194.72 Cr.

As of 10th June, Jenburkt Pharmaceuticals Ltd. has a market capitalization of 519.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Jenburkt Pharmaceuticals reported Net Sales of 168.74 Cr and a Net Profit of 34.73 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with Shareholder's Funds amounting to 171.78 Cr and Total Assets of 194.72 Cr.

Who are in the management team of Jenburkt Pharma?

The management team of Jenburkt Pharma includes Ashish U Bhuta (Chairman & Managing Director), Dilip H Bhuta (Whole Time Director & CFO), and Ashish R Shah (Company Secretary & Compliance Officer), along with several independent directors. They are responsible for the company's strategic direction and regulatory compliance.

The management team of Jenburkt Pharma includes the following individuals:<BR><BR>1. **Ashish U Bhuta** - Chairman & Managing Director<BR>2. **Dilip H Bhuta** - Whole Time Director & CFO<BR>3. **Ashish R Shah** - Company Secretary & Compliance Officer<BR><BR>Additionally, the Board of Directors features several independent directors:<BR><BR>1. **Bharat V Bhate** - Non-Executive & Independent Director<BR>2. **Rameshchandra J Vora** - Non-Executive & Independent Director<BR>3. **Arun R Raskapurwala** - Non-Executive & Independent Director<BR>4. **Hina Ravindra Mehta** - Non-Executive & Independent Director<BR>5. **Sumit Ajaybhai Thakkar** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and ensuring compliance with regulations.

Who are the peers of the Jenburkt Pharma?

Jenburkt Pharma's peers include Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcare, Bafna Pharma, Haleos Labs, CCME Global, Albert David, and Influx Health. In terms of management risk and growth, Kilitch Drugs stands out positively, while Bafna Pharma has the highest 1-year return at 135.33%, and Anuh Pharma has the lowest at -28.11%.

Peers: The peers of Jenburkt Pharma are Anuh Pharma, Kilitch Drugs, Zim Laboratories, Amanta Healthcar, Bafna Pharma, Haleos Labs Limi, CCME Global, Albert David, and Influx Health.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kilitch Drugs and Jenburkt Pharma, while Average management risk is found at Anuh Pharma, Zim Laboratories, Amanta Healthcar, Haleos Labs Limi, and Albert David, and the rest. Below Average management risk is noted at Bafna Pharma, CCME Global, and Influx Health. Growth is Excellent at Kilitch Drugs, while Average growth is seen at Influx Health and the rest. Below Average growth is found at Anuh Pharma, Zim Laboratories, Amanta Healthcar, Bafna Pharma, Haleos Labs Limi, CCME Global, and Albert David.<BR><BR>Return Snapshot: Bafna Pharma has the highest 1-year return at 135.33%, while Anuh Pharma has the lowest at -28.11%. Jenburkt Pharma's 1-year return of -8.13% is better than Anuh Pharma's but worse than Bafna Pharma's. Additionally, Haleos Labs Limi and CCME Global have negative six-month returns.

What does Jenburkt Pharma do?

Jenburkt Pharmaceuticals Ltd. manufactures and markets specialty pharmaceutical formulations and healthcare products. As of March 2026, it reported net sales of 45 Cr and a net profit of 11 Cr, with a market cap of INR 519 Cr.

Overview: <BR>Jenburkt Pharmaceuticals Ltd. is engaged in the manufacturing and marketing of specialty and high-quality pharmaceutical formulations and healthcare products, operating within the Pharmaceuticals & Biotechnology industry and classified as a Micro Cap company.<BR><BR>History: <BR>Incorporated in 1985, Jenburkt Pharmaceuticals was formed as a joint venture by the Bhuta family to diversify into the healthcare and pharmaceutical industry. The latest quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 45 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 11 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 519 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.04 <BR>Return on Equity: 20.70% <BR>Price to Book: 2.81 <BR><BR>Contact Details: <BR>Address: Nirmala Apartment P B No 37396, 93 Jayprakash Road Andheri(W) Mumbai Maharashtra : 400058 <BR>Tel: 91-22-66943121/67603603 <BR>Email: investor@jenburkt.com <BR>Website: http://www.jenburkt.com

Are Jenburkt Pharmaceuticals Ltd. latest results good or bad?

Jenburkt Pharmaceuticals Ltd. reported strong Q4 FY26 results, with a net profit of ₹10.85 crores, an 82.97% quarter-on-quarter increase, and a revenue of ₹44.63 crores, reflecting solid growth. The company also improved its operating margins significantly and maintains a debt-free balance sheet, indicating a positive financial position overall.

Jenburkt Pharmaceuticals Ltd. has reported strong results for Q4 FY26, indicating a positive performance overall. The company achieved a net profit of ₹10.85 crores, which marks an impressive 82.97% increase compared to the previous quarter and a 27.05% increase year-on-year. This significant growth in net profit is complemented by a revenue of ₹44.63 crores, reflecting a quarter-on-quarter growth of 3.74% and an 8.72% increase year-on-year.<BR><BR>One of the standout features of this quarter is the remarkable recovery in operating margins, which rose to 31.93%, up from 17.25% in the previous quarter. This increase of 1,468 basis points is primarily attributed to a substantial reduction in employee costs, suggesting improved operational efficiency.<BR><BR>Overall, the financial performance showcases strong capital efficiency, with a return on equity (ROE) of 18.99%. The company's debt-free balance sheet further enhances its financial stability. Given these results, Jenburkt Pharmaceuticals appears to be in a good position, demonstrating both profitability and effective cost management. However, the sustainability of these margins and revenue growth will be crucial to monitor in future quarters.

Is Jenburkt Pharma technically bullish or bearish?

As of December 1, 2025, the market trend is mildly bearish, indicated by daily moving averages and monthly MACD, despite mixed signals from the KST and a lack of strong bullish indicators in the RSI and Dow Theory.

As of 1 December 2025, the technical trend has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating a bearish sentiment and the monthly MACD showing a mildly bearish outlook. The weekly Bollinger Bands also reflect a bearish trend, while the KST presents a mixed view with a mildly bullish weekly signal but a mildly bearish monthly signal. Overall, the lack of strong bullish signals in the RSI and Dow Theory further supports the mildly bearish stance.

How has been the historical performance of Jenburkt Pharma?

Jenburkt Pharma has shown consistent growth in net sales and profits, with net sales increasing from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, and profit after tax rising from INR 16.50 crore to INR 32.06 crore during the same period, indicating strong financial health.

Answer:<BR>The historical performance of Jenburkt Pharma shows a consistent growth trend in net sales and profits over the years.<BR><BR>Breakdown:<BR>Jenburkt Pharma's net sales have steadily increased from INR 109.29 crore in March 2021 to INR 151.69 crore in March 2025, reflecting a strong upward trajectory. The total operating income followed a similar pattern, rising from INR 118.89 crore in March 2020 to INR 151.69 crore in March 2025. Operating profit (PBDIT) also saw significant growth, climbing from INR 24.15 crore in March 2021 to INR 47.11 crore in March 2025, indicating improved operational efficiency. Profit before tax rose from INR 21.64 crore in March 2021 to INR 43.93 crore in March 2025, while profit after tax increased from INR 16.50 crore to INR 32.06 crore during the same period. The company's earnings per share (EPS) improved from INR 35.95 in March 2021 to INR 72.7 in March 2025, showcasing enhanced shareholder value. On the balance sheet, total assets grew from INR 104.31 crore in March 2020 to INR 194.72 crore in March 2025, with total liabilities also increasing but at a controlled pace. Cash flow from operating activities improved significantly, reaching INR 27 crore in March 2025, compared to INR 8 crore in March 2024, while the closing cash and cash equivalents rose to INR 7 crore in March 2025 from INR 4 crore in March 2024. Overall, Jenburkt Pharma has demonstrated robust financial health and growth across multiple dimensions over the years.

Is Jenburkt Pharma overvalued or undervalued?

As of October 23, 2025, Jenburkt Pharma is considered overvalued with a PE ratio of 14.79 and an EV to EBIT of 12.31, despite outperforming the Sensex, indicating caution for potential investors.

As of 23 October 2025, Jenburkt Pharma's valuation grade has moved from fair to expensive, indicating a shift towards overvaluation. The company is currently assessed as overvalued, with a PE ratio of 14.79, an EV to EBIT of 12.31, and an ROCE of 23.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.47, while Cipla is valued more attractively with a PE of 24.64.<BR><BR>The valuation metrics suggest that Jenburkt Pharma is trading at a premium relative to its earnings potential, especially when considering the PEG ratio of 0.94, which indicates growth at a reasonable price but still reflects a higher valuation compared to peers like Dr Reddy's Labs, which boasts a PE of 18.8 and an EV to EBITDA of 12.41. While Jenburkt Pharma has outperformed the Sensex over the past year with a return of 12.62% compared to the Sensex's 5.59%, the overall valuation suggests caution for potential investors.

Who are the top shareholders of the Jenburkt Pharma?

The top shareholders of Jenburkt Pharma are Bhuta Holdings Private Limited with 13.96%, and individual investors who collectively own 43.55%. The largest public shareholder is Nirmala Vinodkumar Daga, holding 3.3%, with no institutional investors currently involved.

The top shareholders of Jenburkt Pharma include Bhuta Holdings Private Limited, which holds the highest stake at 13.96%. Additionally, individual investors collectively own 43.55% of the company. The highest public shareholder is Nirmala Vinodkumar Daga, with a holding of 3.3%. There are no institutional investors or mutual funds currently holding shares in the company.

Has Jenburkt Pharma declared dividend?

Yes, Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend, with an ex-date of July 23, 2024. Despite this significant dividend announcement, the dividend yield remains at 0%, while the company has shown strong price appreciation over various periods.

Jenburkt Pharmaceuticals Ltd. has declared a 153% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 153%<BR>- Ex-date: 23 Jul 24<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 4.19%, with a dividend return of 0%, resulting in a total return of 4.19%.<BR><BR>Over the past year, the price return was 55.55%, with a dividend return of 0%, leading to a total return of 55.55%.<BR><BR>In the 2-year period, the price return was 79.44%, with a dividend return of 0%, culminating in a total return of 79.44%.<BR><BR>For the 3-year period, the price return was 135.81%, with a dividend return of 2.48%, resulting in a total return of 138.29%.<BR><BR>In the 4-year period, the price return was 150.9%, with a dividend return of 4.55%, leading to a total return of 155.45%.<BR><BR>Over the last 5 years, the price return was 238.92%, with a dividend return of 6.11%, culminating in a total return of 245.03%.<BR><BR>Overall, Jenburkt Pharmaceuticals Ltd. has declared a significant dividend, but the dividend yield remains at 0%. The total returns over various periods indicate strong price appreciation, particularly over the longer term, suggesting positive performance in the company's stock value.